Acasti Pharma reported $18.67M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Acasti Pharma USD 18.67M 1.81M Dec/2025
Addus HomeCare USD 103.06M 21.45M Mar/2026
Amarin USD 131.06M 3.6M Mar/2026
Cassava Sciences USD 86.57M 8.93M Mar/2026
Knight Therapeutics CAD 76.45M 5.43M Dec/2025
Option Care Health USD 177.32M 55.3M Mar/2026
Organigram Holdings CAD 7.58M 20.62M Dec/2025
Tilray USD 264.83M 43.16M Jun/2025